Stockscreener 앱 받기
17.97
0.45%
0.08
시장 영업 전:
17.95
-0.02
-0.11%
Apellis Pharmaceuticals Inc 주식(APLS)의 최신 뉴스
Complement 3 Glomerulopathy Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | NovelMed Therapeutics, Apellis Pharma, Novartis, Amyndas Pharma - Barchart.com
Apellis Pharmaceuticals, Inc. (APLS) surpasses Q4 earnings and revenue estimates - MSN
APLS: Cantor Fitzgerald Lowers Price Target While Maintaining Ov - GuruFocus
Apellis wins new buy at Roth on Syfovre prospects - MSN
Cantor Fitzgerald Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price - MarketBeat
Price-Driven Insight from (APLS) for Rule-Based Strategy - Stock Traders Daily
Bank of Nova Scotia Acquires 861,413 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Does Apellis Pharmaceuticals' (APLS) New Board Member Reveal a Deeper R&D Commercialization Strategy Shift? - simplywall.st
Apellis Pharmaceuticals, Inc. $APLS Shares Bought by HighVista Strategies LLC - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Assessing Apellis Pharmaceuticals (APLS) Valuation After Weaker Returns And EMPAVELI Label Expansion - Yahoo Finance
Integral Health Asset Management LLC Purchases Shares of 250,000 Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals (APLS) Receives Buy Rating Amid Growth P - GuruFocus
Analysts’ Top Healthcare Picks: Apellis Pharmaceuticals (APLS), Argenx Se (ARGX) - The Globe and Mail
Apellis (NASDAQ: APLS) CEO gifts 129,738 shares via family trusts - Stock Titan
Apellis Pharmaceuticals, Inc.Common Stock (NQ: APLS - The Chronicle-Journal
APLS: Roth Capital Initiates Coverage with 'Buy' Rating at $31.0 - GuruFocus
Apellis stock wins new Buy at Roth on Syfovre (APLS:NASDAQ) - Seeking Alpha
Apellis Pharmaceuticals (NASDAQ:APLS) Coverage Initiated at Roth Mkm - MarketBeat
Roth Capital initiates coverage of Apellis Pharmaceuticals (APLS) with buy recommendation - MSN
Here is Why JPMorgan is Overweight on Apellis Pharma (APLS) - Finviz
10 Most Shorted Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
How Apellis Adding Ex-Pfizer R&D Chief Mikael Dolsten to Its Board Will Impact Apellis (APLS) Investors - simplywall.st
Rhenman & Partners Asset Management AB Has $5.26 Million Stock Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals Balances Growth With Revenue Headwinds - The Globe and Mail
Apellis Sells Aspaveli Ex-US Royalties to Sobi for Up to $300M - MSN
Apellis Adds Ex Pfizer R&D Chief To Board As Growth Plans Evolve - Sahm
Analysts Are Bullish on These Healthcare Stocks: Veeva Systems (VEEV), Apellis Pharmaceuticals (APLS) - The Globe and Mail
(APLS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
JP Morgan Raises Price Target for APLS, Maintains Overweight Rat - GuruFocus
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $37.00 at JPMorgan Chase & Co. - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Raised to $20.00 at Mizuho - MarketBeat
APLS: Mizuho Maintains Rating, Raises Price Target | APLS Stock News - GuruFocus
Assessing Apellis Pharmaceuticals: Insights From 11 Financial Analysts - Benzinga
APLS Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Update Recap: Will Apellis Pharmaceuticals Inc benefit from geopolitical trendsMarket Performance Summary & Daily Technical Forecast Reports - baoquankhu1.vn
Apellis Pharmaceuticals (APLS) director receives new stock options and RSUs - Stock Titan
Apellis (APLS) director Mikael Dolsten submits initial Form 3 insider filing - Stock Titan
Apellis Pharmaceuticals (APLS) Stock Analysis: Exploring a 62.73% Upside Potential in Biotech - DirectorsTalk Interviews
Apellis Pharmaceuticals Details SYFOVRE, EMPAVELI Growth Plans and FcRn Gene-Editing Push at TD Cowen Conf. - MarketBeat
Analysts Offer Insights on Healthcare Companies: Arcellx Inc (ACLX) and Apellis Pharmaceuticals (APLS) - The Globe and Mail
Apellis adds former Pfizer research chief to board - Investing.com
Apellis Pharmaceuticals appoints Mikael Dolsten to board of directors - Investing.com Australia
Apellis Pharmaceuticals2026 Funding Rounds & List of Investors - Tracxn
Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Vanguard Group Inc. - MarketBeat
Apellis Pharmaceuticals Adds Mikael Dolsten to Board - TipRanks
Apellis Pharmaceuticals appoints Mikael Dolsten to board of directors By Investing.com - Investing.com India
Apellis adds former Pfizer research chief to board By Investing.com - Investing.com Canada
Apellis Appoints Mikael Dolsten, M.D., Ph.D., To Board - citybiz
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors - Bitget
Mikael Dolsten joins Apellis Board as Class I director - TradingView
Mikael Dolsten joins Apellis (NASDAQ: APLS) board with equity grants - Stock Titan
Pfizer veteran who led R&D for 16 years joins Apellis board - Stock Titan
A Look At Apellis Pharmaceuticals (APLS) Valuation After 2025 Results And Softer Syfovre Growth Outlook - simplywall.st
Apellis Pharmaceuticals (NASDAQ:APLS) Lowered to Sell Rating by Wall Street Zen - MarketBeat
HC Wainwright Issues Optimistic Outlook for APLS Earnings - MarketBeat
Assessing Apellis Pharmaceuticals (APLS) Valuation After Prolonged Share Price Weakness - Yahoo Finance
1.20%
0.06%
자본화:
|
볼륨(24시간):